(NASDAQ: FHTX) Foghorn Therapeutics's forecast annual revenue growth rate of 21.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Foghorn Therapeutics's revenue in 2025 is $24,173,000.On average, 4 Wall Street analysts forecast FHTX's revenue for 2025 to be $1,732,756,610, with the lowest FHTX revenue forecast at $1,498,044,179, and the highest FHTX revenue forecast at $1,940,673,836. On average, 4 Wall Street analysts forecast FHTX's revenue for 2026 to be $2,177,251,756, with the lowest FHTX revenue forecast at $1,724,164,055, and the highest FHTX revenue forecast at $2,821,410,753.
In 2027, FHTX is forecast to generate $2,385,564,692 in revenue, with the lowest revenue forecast at $1,950,283,931 and the highest revenue forecast at $2,821,410,753.